Scholarlink

Background <p>Hematopoietic stem cell transplantation (HSCT) is an effective treatment for refractory or relapsed acute lymphoblastic leukemia (ALL). However, persistent challenges, such as post-transplant relapse and Epstein-Barr virus (EBV) reactivation, remain unresolved. The current standard prophylactic strategies are complex to implement and demonstrate inconsistent efficacy. Optimizing methods to prevent cancer recurrence and control viremia is crucial for enhancing patient outcomes.</p> Case presentation <p>We present two novel cases of patients with B-cell ALL who developed EBV viremia following allogeneic HSCT and received blinatumomab as a relapse prophylaxis. Both cases achieved sustained EBV eradication (for more than 3 months) following a course of blinatumomab (8&#xa0;µg/day × 8 days), initiated during asymptomatic viremia at 3 months post-transplant. Both patients demonstrated favorable therapeutic outcomes.</p> Conclusions <p>Blinatumomab may represent a promising therapeutic option for managing EBV viremia and providing relapse prophylaxis in patients with B-cell ALL following allogeneic HSCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Two birds, one BiTE: blinatumomab achieves concurrent B-ALL control and EBV clearance in post-HSCT patients: two cases report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Yawei Zhang,
  • Zebin Luo,
  • Miner Gu,
  • Xiaoping Guo,
  • Fenying Zhao,
  • Xiaojun Xu

摘要

Background

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for refractory or relapsed acute lymphoblastic leukemia (ALL). However, persistent challenges, such as post-transplant relapse and Epstein-Barr virus (EBV) reactivation, remain unresolved. The current standard prophylactic strategies are complex to implement and demonstrate inconsistent efficacy. Optimizing methods to prevent cancer recurrence and control viremia is crucial for enhancing patient outcomes.

Case presentation

We present two novel cases of patients with B-cell ALL who developed EBV viremia following allogeneic HSCT and received blinatumomab as a relapse prophylaxis. Both cases achieved sustained EBV eradication (for more than 3 months) following a course of blinatumomab (8 µg/day × 8 days), initiated during asymptomatic viremia at 3 months post-transplant. Both patients demonstrated favorable therapeutic outcomes.

Conclusions

Blinatumomab may represent a promising therapeutic option for managing EBV viremia and providing relapse prophylaxis in patients with B-cell ALL following allogeneic HSCT.